Didn't say 12 was conclusive. Just correcting your N of 6. It is true that the paper you cite has N of 6. But that is just for Ulcerative colitis. The announcement was about both Chrohn’s and Ulcerative colitis. ClinicalTrials.gov actually lists them as 2 separate trials. So maybe the publication was just about 1 of those trials, wereas the conference presentation and MSB announcement was about both.
Crohn’s Disease, page-107
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.0¢ |
Change
-0.005(0.54%) |
Mkt cap ! $1.056B | |||
| Open | High | Low | Value | Volume |
| 92.0¢ | 92.0¢ | 91.5¢ | $294.8K | 320.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 171361 | 91.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 92.0¢ | 6860 | 7 |
View Market Depth
| Last trade - 10.20am 18/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |